Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Inavolisib (GDC-0077) is an orally available and selective inhibitor of PI3Kα (IC50=0.038 nM). Inavolisib is more selective for mutant versus wild-type PI3Kα. Inavolisib exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 203.00 | |
5 mg | In stock | $ 413.00 | |
10 mg | In stock | $ 675.00 | |
25 mg | In stock | $ 973.00 | |
50 mg | In stock | $ 1,430.00 | |
100 mg | In stock | $ 1,930.00 | |
200 mg | In stock | $ 2,590.00 | |
500 mg | In stock | $ 3,870.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 425.00 |
Description | Inavolisib (GDC-0077) is an orally available and selective inhibitor of PI3Kα (IC50=0.038 nM). Inavolisib is more selective for mutant versus wild-type PI3Kα. Inavolisib exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. |
Targets&IC50 | PI3Kα:0.038 nM |
In vitro | Inavolisib is >300-fold more selective for PI3Kα over the other class I PI3K isoforms (β, δ, and γ). Inavolisib is >2000-fold more selective over PIK family members. Inavolisib selectively degrades mutant PI3Kα in a proteasome-dependent fashion. When compared to PIK3CA wild-type cells, Inavolisib results in a reduction of PI3K pathway activity biomarkers such as pAKT and pPRAS40, inhibition of cell proliferation. Inavolisib also increased apoptosis in human PIK3CA-mutant breast cancer cell lines to a greater extent [1]. |
In vivo | In patient-derived PIK3CA-mutant breast cancer xenograft models, Inavolisib (p.o.) causes tumor regressions, induction of apoptosis, and a reduction of pAKT, pPRAS40, and pS6RP in a dose-dependent fashion [1]. |
Synonyms | GDC-0077, RG6114 |
Molecular Weight | 407.37 |
Formula | C18H19F2N5O4 |
CAS No. | 2060571-02-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (245.48 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Inavolisib 2060571-02-8 Apoptosis PI3K/Akt/mTOR signaling PI3K GDC-0077 GDC0077 Phosphoinositide 3-kinase Inhibitor RG6114 RG-6114 GDC 0077 inhibit RG 6114 inhibitor